雌激素类中草药在乳腺癌中的安全性评估
本研究探讨雌激素类中草药对乳腺癌细胞及小鼠肿瘤生长的影响。结果显示肉苁蓉和山药水提物在体外显著刺激ER阳性及阴性乳腺癌细胞活力,但动物实验中未显著改变4T1肿瘤大小,且可抑制MDA-MB-231异种移植瘤生长并调节免疫。结论认为对肉苁蓉和山药在乳腺癌患者中使用的担忧可部分缓解。
要点
- 肉苁蓉和山药水提物在体外可刺激乳腺癌细胞增殖,但体内未促进肿瘤生长。
- 两者在免疫缺陷小鼠中抑制三阴性乳腺癌异种移植瘤生长。
- 雌激素类中草药对乳腺癌的影响需结合体外与体内模型综合评估。
核心结论
- 基于临床前研究,肉苁蓉和山药在乳腺癌患者中使用的担忧可部分缓解。
- 雌激素类中草药对乳腺癌生长的潜在有害效应需在细胞和荷瘤小鼠模型中验证。
研究设计与样本
- 研究选取10种雌激素类中草药,检测其水提物对乳腺癌细胞活力及小鼠肿瘤生长的影响。
- 体外使用ER阳性(MDA-MB-361、MCF-7)和ER阴性(SKBR3、MDA-MB-231)乳腺癌细胞。
- 动物实验使用4T1乳腺癌小鼠模型及MDA-MB-231异种移植瘤免疫缺陷小鼠模型。
主要发现
- 肉苁蓉和山药水提物在0.4至1.6 mg/ml浓度下显著刺激ER阳性和ER阴性乳腺癌细胞活力。
- 动物实验中,肉苁蓉和山药处理组4T1肿瘤大小与对照组无显著差异,但山药组增殖细胞数量增加。
- 肉苁蓉和山药处理可增加4T1荷瘤小鼠细胞因子IL-2和IFN-γ产生并调节调节性T细胞。
- 肉苁蓉和山药处理未刺激、反而抑制免疫缺陷小鼠中人三阴性MDA-MB-231乳腺癌异种移植瘤生长。
临床怎么用
- 临床决策时应参考体外与体内实验的综合证据,避免仅凭体外细胞实验判断中草药对乳腺癌的风险。
局限性
- 本研究为临床前研究,结论需进一步临床验证。
- 体外实验显示细胞增殖刺激效应,与体内结果不完全一致,机制需深入探究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An increasing number of breast cancer patients in Asian countries has been found to consume dietary supplements including phytoestrogen-rich Chinese herbal medicines with an expectation to alleviate the side effects of conventional cancer therapies. PURPOSE: The question of whether estrogenic Chinese herbal medicines are beneficial or detrimental to the health of breast cancer patients remains uncertain. STUDY DESIGN: The present study aimed at establishing a systematic approach to look at the safety profiles of estrogenic Chinese herbal medicines (CHM). METHODS: The effects of estrogenic CHM on the growth of human breast cancer cells as well as the progression of breast tumors in mice have been investigated. RESULTS: Our results demonstrated that among 10 selected estrogenic CHM, the aqueous extracts of Cistanche deserticola (CD) and Dioscorea opposita (DO) at 0.4 to 1.6 mg/ml significantly stimulated cell viability in both estrogen receptor (ER)-positive (MDA-MB-361 and MCF-7) and ER-negative (SKBR3 and MDA-MB-231) breast cancer cells. However, results from animal studies showed that no significant difference was found on the size of mouse 4T1 breast tumors in CD- and DO-treated mice when compared with the control group, while the number of proliferative cells were found to be increased in DO-treated group. Besides, CD and DO treatments induced significant immunomodulatory effects on 4T1 tumor-bearing mice by increasing the production of cytokines IL-2 and IFN-γ and modulation of regulatory T-cells. Furthermore, CD and DO treatments did not stimulate, but in fact suppressed human triple-negative MDA-MB-231 breast xenografts growth in immunodeficiency mice. CONCLUSION: The considerable concerns on the use of CD and DO in breast cancer patients could be relieved to some extents upon the findings of this pre-clinical study. The potential harmful effects of estrogenic Chinese herbal medicines on breast cancer growth should be verified in both cell-based and tumor-bearing mice models.
引用
- Yue GG, Wong LS, Leung HW, et al. Evaluation of the safety profiles of estrogenic Chinese herbal medicines in breast cancer. Phytomedicine. 2018. PMID: 30668331. doi:10.1016/j.phymed.2018.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。